TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06544213

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Group
Description: 60 days of strict head down tilt bed rest at all time. No countermeasure program is performed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Countermeasure Supine Bike
Description: 60 days of strict head down tilt bed rest at all time. The exercise starts at 40% of VO2max for 5 minutes, followed by a series of 2-minute high- and low-intensity intervals for 20 minutes. 2-minute high-intensity intervals are at 65% VO2max, 70% VO2max, 80% VO2max, 80% VO2max, 70% VO2max and 65% VO2max. 2-minute low-intensity intervals are at 40% VO2max. 3 minutes at 40% of VO2max will end the exercise.~VO2max is measured for each volunteer in supine position.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Countermeasure AG-Bike
Description: 60 days of strict head down tilt bed rest at all time. The exercise starts at 40% of VO2max for 5 minutes, followed by a series of 2-minute high- and low-intensity intervals for 20 minutes. 2-minute high-intensity intervals are at 65% VO2max, 70% VO2max, 80% VO2max, 80% VO2max, 70% VO2max and 65% VO2max. 2-minute low-intensity intervals are at 40% VO2max. 3 minutes at 40% of VO2max will end the exercise.~VO2max is measured for each volunteer in supine position.~The supine bike exercise is performed in a short arm centrifuge in rotation. Volunteers will start pedalling and the centrifuge will start at 0.15 Gz less than individual's threshold.~Every 4 minutes thereafter, the AG will be increased by 0.15 Gz, synchronized with the ramping up of cycle ergometer interval intensity. The AG will increase only up to 70 % of their tolerance level,.~It will then decrease by 0.15 Gz every 4 minutes, and until the 30-minute exercise is completed.
Study: NCT05918094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental dose: modified XELOX + sintilimab
Description: The treatment option for the modified XELOX group (study group) is 200 mg of sintilimab IV Drip Q3W, 600 mg/m2 of capecitabine PO BID for day 1-14, and oxaliplatin 78 mg/m2 IV Drip Q3W.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose: standard XELOX + sintilimab
Description: The treatment option for the standard XELOX group (control group) is 200 mg of sintilimab IV Drip Q3W, 1000 mg/m2 of capecitabine PO BID for day 1-14, and oxaliplatin 130 mg/m2 IV Drip Q3W.
Study: NCT04861896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Guide (psychoeducation & self-management program)
Description: 12-week long health promotion Smartphone application to support patient's side effects self-management and adherence to endocrine therapy.
Study: NCT05949281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.5 MG Oral Tablet
Description: Colchicine 0.5 mg once-daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once-daily
Study: NCT05527275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone liposome combine with Chidamide
Description: Mitoxantrone Hydrochloride Liposome Injection： Grade 1: 14mg/ m2, D1; Grade 2: 17mg/ m2, D1; Grade 3: 20mg/ m2, D1; Chidamide：20mg twice a week (D1 and D4 or D2 and D5 or D3 and D6) Every 28 days for a cycle, a maximum of 6 cycles of treatment. Mitoxantrone Hydrochloride Liposome Injection RP2D was determined in the phase I trial, and the combination regimen will be used to in the phase II study, with a cycle of every 28 days and a maximum of 6 cycles of treatment.~Subsequently, maintenance treatment was performed: Chidamide, 20mg twice a week, for 1 year.
Study: NCT06524362

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Physiotherapy (PFR)
Description: Intervention: Participants will undergo a structured pelvic floor physiotherapy program for three months.~The program includes:~Eight Personal Sessions: Each session lasts 45 minutes.~Frequency:~Once a week for the first month (four sessions). Biweekly for the next two months (four sessions). Home Exercises: Participants will be guided on pelvic floor exercises to be performed at home throughout the three months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional group
Description: Patients completing three months post-low anterior resection (LAR) for rectal cancer or six weeks post-diversion ileostomy closure following LAR will be recruited to Conventional group after randomization.~Recruited subjects in the conventional group recieves usual care following low anterior resection such as fluid intake, fiber intake, diet, toilet posture, life style advice etc
Study: NCT05658770

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5 days/ week
Description: The type of exercise to be performed will be the one that has shown the greatest benefits for MAGE control in phase 1.~The exercises to be carried out in phase 1 are:~Supervised Aerobic Training intervention (AT): Perform 50 minutes/day, 3 days/week, totalling 150 min/week at moderate intensity, as recommended by WHO, in a range of 65-75% HRMax.~Supervised Aerobic Training plus Resistance Training intervention (AT+RT): Perform 50 minutes/day, 3 days/week, starting with 50% of 1-repetition maximum (1-RM) and follow a progression of increasing loads up to 75% of 1-RM for optimal gains in strength and insulin action.~Supervised High Intensive Interval Training intervention (HIIT): To be considered high intensive the heart rate needs to be above ≥85%. Perform 25 minutes/day, 3 days/week, totalling 75 min/week at a vigorous intensity, as recommended by WHO.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3 days/ week
Description: The type of exercise to be performed will be the one that has shown the greatest benefits for MAGE control in phase 1. The exercises to be carried out in phase 1 are the same as described in the first intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 days/ week
Description: The type of exercise to be performed will be the one that has shown the greatest benefits for MAGE control in phase 1. The exercises to be carried out in phase 1 are the same as described in the first intervention.
Study: NCT05010538

Intervention type: DRUG
Intervention: Sarecycline
Description: 60 mg sarecycline tablets will be given for subjects with a body weight of 33 to 54 kg, 100 mg sarecycline tablets will be given for subjects with a body weight of 55 to 84 kg, and 150 mg tablets will be given for subjects with a body weight between 85 and 136 kg.
Study: NCT05737745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Description: Tracking physical activity and fruit/vegetable intake.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Description: Tracking physical activity and fruit/vegetable intake.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-dynamics
Description: Survivors act as team captains, facilitating interactions between themselves and their support team members and providing goal directed feedback.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-dynamics
Description: Survivors act as team captains, facilitating interactions between themselves and their support team members and providing goal directed feedback.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly virtual sessions- Standard
Description: Weekly 30 minute virtual sessions include support group/team building sessions and 15 minutes of physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Newsletters- Standard
Description: Weekly newsletters support attainment of physical activity and nutrition goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Newsletters- Yoga
Description: Weekly newsletters support attainment of physical activity and nutrition goals, while including mindfulness principles.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly virtual sessions- Yoga
Description: Weekly 30 minute virtual sessions include support group/team building sessions and 15 minutes of yoga.
Study: NCT06344195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 mg
Description: Valtrex 2g immediate dose followed by 500mg 2 times daily for 3 days along with the analgesic (SOS, if needed) for 6 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Sodium 550mg
Description: 550mg (as needed, SOS) for 6 days
Study: NCT05658614

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sm14 recombinant vaccine+ GLA-SE adjuvant
Description: rSm14 - recombinant protein (GMP produced) - 50ug / injection GLA-SE- synthetic Glucopyranosyl lipid A in stable emulsion: 2.5ug / injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sm14 recombinant vaccine+ GLA-SE adjuvant
Description: rSm14 - recombinant protein (GMP produced) - 50ug / injection GLA-SE- synthetic Glucopyranosyl lipid A in stable emulsion: 2.5ug / injection
Study: NCT05170828

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: pre-transplant conditioning treatment

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: pre-transplant conditioning treatment

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: pre-transplant conditioning treatment
Study: NCT04867577

Intervention type: DIAGNOSTIC_TEST
Intervention: CT scan of lung and spine
Description: Dual energy CT scan of thorax and spine
Study: NCT05170828

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine
Description: pre-transplant conditioning treatment

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine
Description: pre-transplant conditioning treatment

Intervention type: RADIATION
Group type: OTHER
Intervention: Total Body Irradiation
Description: pre-transplant conditioning treatment

Intervention type: RADIATION
Group type: OTHER
Intervention: Total Body Irradiation
Description: pre-transplant conditioning treatment

Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan
Description: pre-transplant conditioning treatment

Intervention type: DRUG
Group type: OTHER
Intervention: Mesna
Description: given with cyclophosphamide

Intervention type: DRUG
Group type: OTHER
Intervention: Mesna
Description: given with cyclophosphamide

Intervention type: DRUG
Group type: OTHER
Intervention: Mesna
Description: given with cyclophosphamide

Intervention type: DRUG
Group type: OTHER
Intervention: Sirolimus
Description: post-transplant treatment for GVHD

Intervention type: DRUG
Group type: OTHER
Intervention: Sirolimus
Description: post-transplant treatment for GVHD

Intervention type: DRUG
Group type: OTHER
Intervention: Sirolimus
Description: post-transplant treatment for GVHD

Intervention type: DRUG
Group type: OTHER
Intervention: Mycophenolate Mofetil
Description: post-transplant treatment for GVHD

Intervention type: DRUG
Group type: OTHER
Intervention: Mycophenolate Mofetil
Description: post-transplant treatment for GVHD

Intervention type: DRUG
Group type: OTHER
Intervention: Mycophenolate Mofetil
Description: post-transplant treatment for GVHD

Intervention type: DRUG
Group type: OTHER
Intervention: Filgrastim
Description: post-transplant treatment for GVHD

Intervention type: DRUG
Group type: OTHER
Intervention: Filgrastim
Description: post-transplant treatment for GVHD

Intervention type: DRUG
Group type: OTHER
Intervention: Filgrastim
Description: post-transplant treatment for GVHD

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: post-transplant treatment for GVHD

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: post-transplant treatment for GVHD

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: post-transplant treatment for GVHD

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bone Marrow Transplant
Description: Transplant with investigational bone marrow product

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bone Marrow Transplant
Description: Transplant with investigational bone marrow product

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bone Marrow Transplant
Description: Transplant with investigational bone marrow product
Study: NCT06182683

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: optical coherence tomography and fractional flow reserve
Description: The assessment of pre-procedural lesions and optimization status of implanted stents will involve both intracoronary imaging and physiological indices.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angiography
Description: The assessment of pre-procedural lesions and optimization status of implanted stents will be determined by conventional coronary angiography

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Coronary angiography
Description: The assessment of pre-procedural lesions and optimization status of implanted stents will be determined by conventional coronary angiography
Study: NCT05512325

Intervention type: DRUG
Intervention: Gene evolution and molecular response under Bevacizumab treatment
Description: Patients with glioma were routinely treated with temozolomide chemotherapy from the 4th week after operation, for 5 days continuously, once every 4 weeks, with a single dose as follows: Single dose = BSA (body surface area) \* 150mg/m2/day BSA(Body Surface Area)=\[weight (kg)\* height (cm)/3600\]2, According to the molecular pathological grade (WHO CNS5 grade), it is decided whether to combine radiotherapy (GBM combined with radiotherapy) and temozolomide combined with bevacizumab (600mg) in the course of tumor progression, Recording image changes
Study: NCT06527716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teaching Strategy
Description: Experimental group:~Get involved in the LINE digital media course learning platform.~1. LINE digital media course study period:~   Research subjects need to complete the aforementioned three pre-measurement forms before they can join the LINE digital media course. In this lesson plan design, at the end of a single class, there will be a summary of the key points of the class; after the end of a single class, there will be 5 to 10 questions accompanying the class. When the research subjects have finished answering, Regardless of whether the answer is correct or not, the system will display Problem Solution Analysis. The study time for this stage is 1 month.~2. WorkShop Learning~Control group:~Intervention in regular education course learning platform. The above-mentioned digital media courses will be placed on the educational platform of the college for research subjects to watch and learn.
Study: NCT06080984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oncolytic Virus SDJ001
Description: Patients in the study receive intratumoral treatment with SDJ001 at two dose levels: 5x10\^11 and 1x10\^12 pfu per person. At the current dose levels, intratumoral injection is administered on the first day of each treatment cycle. Each treatment cycle consists of three weeks, continuing until tumor growth is observed following injection or until the patient experiences intolerable toxic effects.~Ultrasound-guided injection may be used when necessary (2.0 mL for tumors with a diameter \>2.5 cm, 1.0 mL for diameters of 1.5-2.5 cm, 0.5 mL for diameters of 0.5-1.5 cm, and 0.1 mL for diameters \<0.5 cm, with a maximum of 4 mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oncolytic Virus YD06-1
Description: Patients in the study receive intratumoral treatment with a novel oncolytic virus YD06-1 at a concentration of 10\^6 pfu/mL to 10\^8 pfu/ml following a dose escalation plan. Each subject receives only one injection at the corresponding concentration, with the dose determined based on the size of the tumor mass. (Diameter ≤1.5 cm, maximum of 1 mL; diameter 1.5-2.5 cm, maximum of 2 mL; diameter greater than 2.5 cm, maximum of 4 mL). The second dose is administered three weeks after the first dose, followed by subsequent doses at two-week intervals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oncolytic Virus YD06-1
Description: Patients in the study receive intratumoral treatment with a novel oncolytic virus YD06-1 at a concentration of 10\^6 pfu/mL to 10\^8 pfu/ml following a dose escalation plan. Each subject receives only one injection at the corresponding concentration, with the dose determined based on the size of the tumor mass. (Diameter ≤1.5 cm, maximum of 1 mL; diameter 1.5-2.5 cm, maximum of 2 mL; diameter greater than 2.5 cm, maximum of 4 mL). The second dose is administered three weeks after the first dose, followed by subsequent doses at two-week intervals.
Study: NCT05615623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate
Description: Blood Brain Barrier Disruption (BBBD) via Exablate Type 2 system with microbubble resonators on the day of Doxorubicin infusion to treat DIPG brain tumors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin infusion
Study: NCT05732571

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breathing techniques over 12 sessions / 6 weeks inc yoga
Description: as above
Study: NCT04613921

Intervention type: OTHER
Intervention: Observational Protocol
Description: The cohorts will be followed for one year after LT transplantation except for group 3 (1-year follow-up after inclusion)

Intervention type: OTHER
Intervention: Observational Protocol
Description: The cohorts will be followed for one year after LT transplantation except for group 3 (1-year follow-up after inclusion)

Intervention type: OTHER
Intervention: Observational Protocol
Description: The cohorts will be followed for one year after LT transplantation except for group 3 (1-year follow-up after inclusion)
Study: NCT06504979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth follow-up of post-intensive care syndrome
Description: Using a telehealth platform for the detection of the emotional, neuropsychological and physical PICS-related sequelae along 12 months in ICU survivors
Study: NCT06447454

Intervention type: RADIATION
Intervention: radiotherapy
Description: radiotherapy

Intervention type: DRUG
Intervention: gemcitabine + cisplatin
Description: Gemcitabine 1000mg/m² intravenous infusion over 30 minutes, cisplatin 25mg/m² intravenous infusion, on day 1 and day 8, every 3 weeks.

Intervention type: DRUG
Intervention: slulimumab
Description: Slulimumab, 4.5mg/kg intravenous infusion, Q3W
Study: NCT04854694

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FaceView Mask™
Description: transparent surgical N95 respirator designed to improve communication

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conventional surgical N95 respirator
Description: standard N95 respirator
Study: NCT06019546

Intervention type: OTHER
Intervention: PEQUOD
Description: During cardiopulmonary bypass registration of the parameters of interest by the Livanova BE-CAPTA monitor. After surgery, registration of creatinine values up to 48 postoperative hours.
Study: NCT06162364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR
Description: playing a video using VR

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR
Description: playing a video using VR

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: theoretical training
Description: Training was provided through theoretical education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training with video
Description: Training was given with two-dimensional video
Study: NCT04466293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice Architecture
Description: 1. Providers will receive general training on TPT benefits, indications, and contra-indications.~2. Providers will be provided with updated ART and TPT prescribing approach. This will be adapted to the country context and may include a pre-printed prescription pad (Mozambique), adaptations in clinical stationary (Zimbabwe), or adaptations to an electronic prescribing system (Malawi).~3. The pharmacy or clinician (if the clinician dispenses) will dispense ART, cotrimoxazole, and TPT as prescribed
Study: NCT05725538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COVIDReApp Group
Description: The COVIDReApp group will be required to complete an exercise program guided by an m-health system for three times per week during 24 weeks. A 60-minute program, following the recommendations of the American College of Sports Medicine. The daily session will be divided into:~* Warm-up: 5 min. walking so that the patient can hold a conversation , monopodial balance exercise, core exercise and other respiratory and joint mobility exercises.~* Aerobic training: Walking for 10 to 20 min. so that the patient can maintain a conversation, but having to stop to breathe from time to time.~* Strengthening: It will focus on 7 exercises. a) squats, b) dead weight with stiff legs, c) lateral pull-ups, d) inverted flies, e) flies, f) unilateral rowing and g) lateral raises.~* Cool down: It will consist of stretching exercises. a) shoulders, b) triceps, c) chest, d) quadriceps, e) hamstrings, and f) back.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Participants will receive the same intervention in the traditional way, they will receive the exercise program in paper format. They will receive a document with photos and descriptions of the exercises to be performed. Their doctors will determine if the patients will be able to exercise regularly and they will perform them for 24 weeks.
Study: NCT05542576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMDX2011P
Description: AMDX2011P single bolus injection intravenous for diagnostic review

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMDX2011P
Description: AMDX2011P single bolus injection intravenous for diagnostic review

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMDX2011P
Description: AMDX2011P single bolus injection intravenous for diagnostic review

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMDX2011P
Description: AMDX2011P single bolus injection intravenous for diagnostic review
Study: NCT05764850

Intervention type: GENETIC
Intervention: Genome sequencing
Description: 100 extensively phenotyped pediatric and young adult patients for genotyping, metabolomic and lipidomic analyses. Polygenic risk scores for type 1 diabetes and cardiovascular disease will be performed.~For patients older than 6 years who agree to do a second visit (optional), a Mixed Meal Tolerance Test (MMTT: the gold standard for assessing beta cell function) will be done as well as transcriptomic analysis.

Intervention type: GENETIC
Intervention: Genome sequencing
Description: 100 extensively phenotyped pediatric and young adult patients for genotyping, metabolomic and lipidomic analyses. Polygenic risk scores for type 1 diabetes and cardiovascular disease will be performed.~For patients older than 6 years who agree to do a second visit (optional), a Mixed Meal Tolerance Test (MMTT: the gold standard for assessing beta cell function) will be done as well as transcriptomic analysis.